Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues

Gene

Volumn 506, Issue 1, 2012, Pages 62-68

  Hasmats, Johanna ^a   Kupershmidt, Ilya ^a,b   Rodríguez Antona, Cristina ^c,d   Su, Qiaojuan Jane ^b   Khan, Muhammad Suleman ^e   Jara, Carlos ^f   Mielgo, Xabier ^f   Lundeberg, Joakim ^a   Green, Henrik ^a,e  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b NextBio   (United States)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e LINKÖPING UNIVERSITY   (Sweden)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Carboplatin; Gene expression microarrays; Meta analysis; Paclitaxel; Single nucleotide polymorphism; Toxicity

Indexed keywords

ABC TRANSPORTER A1; ADD2 PROTEIN; AGT PROTEIN; AQP3 PROTEIN; ATM PROTEIN; C5ORF13 PROTEIN; CA2 PROTEIN; CAPN3 PROTEIN; CARBOPLATIN; CCNF PROTEIN; CNOT2 PROTEIN; DEFB1 PROTEIN; EPOR PROTEIN; GLUCOSE TRANSPORTER 3; HCN3 PROTEIN; LILRB3 PROTEIN; MAP4K4 PROTEIN; PACLITAXEL; PDS5B PROTEIN; PIP4K2A PROTEIN; PROTEIN; STXBP2 PROTEIN; UNCLASSIFIED DRUG; YARS PROTEIN;

ARTICLE; BASAL GANGLION; BONE MARROW; BONE MARROW SUPPRESSION; BRAIN CORTEX; CANCER CHEMOTHERAPY; CANCER PATIENT; CEREBELLUM; COMPUTER MODEL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; KIDNEY; LIVER; LUNG CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOTOR CORTEX; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; PARIETAL LOBE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD; SPINAL GANGLION; THALAMUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW; CARBOPLATIN; CELL CYCLE PROTEINS; DATABASES, GENETIC; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; LUNG NEOPLASMS; MALE; NEOPLASMS; NERVOUS SYSTEM DISEASES; OVARIAN NEOPLASMS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84864511649     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.06.053     Document Type: Article

References (30)

1. Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature 455 (2008) 1061-1068.
2. Bergmann T.K., et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011, 11:113-120.
3. Brazma A., et al. ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 2003, 31:68-71.
4. Brem R.B., Yvert G., Clinton R., Kruglyak L. Genetic dissection of transcriptional regulation in budding yeast. Science 2002, 296:752-755.
5. Chan S.K., Griffith O.L., Tai I.T., Jones S.J. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol. Biomarkers Prev. 2008, 17:543-552.
6. Chen R., et al. FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease. Genome Biol. 2008, 9:R170.
7. Eaves I.A., et al. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Res. 2002, 12:232-243.
8. Edgar R., Domrachev M., Lash A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30:207-210.
9. Gardiner-Garden M., Littlejohn T.G. A comparison of microarray databases. Brief Bioinform. 2001, 2:143-158.
10. Green H., Soderkvist P., Rosenberg P., Horvath G., Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 2006, 12:854-859.
11. Green H., Soderkvist P., Rosenberg P., Horvath G., Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci. 2008, 97:2045-2048.
12. Green H., et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 2009, 104:130-137.
13. Jiang H., et al. Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinforma. 2004, 5:81.
14. Kaller M., et al. Comparison of PrASE and pyrosequencing for SNP genotyping. BMC Genomics 2006, 7:291.
15. Karp C.L., et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 2000, 1:221-226.
16. Kim H.S., et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 2009, 113:264-269.
17. Kupershmidt I., et al. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 2010, 5.
18. Leskela S., et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 2011, 11:121-129.
19. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 2007, 25:4528-4535.
20. McGuire W.P., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334:1-6.
21. Okazaki T., Jiao L., Chang P., Evans D.B., Abbruzzese J.L., Li D. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin. Cancer Res. 2008, 14:2042-2048.
22. Rhodes D.R., Barrette T.R., Rubin M.A., Ghosh D., Chinnaiyan A.M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002, 62:4427-4433.
23. Rodriguez-Antona C., et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008, 8:268-277.
24. Schadt E.E., et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003, 422:297-302.
25. Scoles D.R., et al. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol. Oncol. 2010, 116:109-116.
26. Sherlock G., et al. The Stanford Microarray Database. Nucleic Acids Res. 2001, 29:152-155.
27. Sissung T.M., et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 2006, 42(17):2893-2896.
28. Sparreboom A., et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2031-2035.
29. Walle T., Walle U.K., Kumar G.N., Bhalla K.N. Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos. 1995, 23:506-512.
30. Yvan-Charvet L., Wang N., Tall A.R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 2010, 30:139-143.